Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach

被引：0

作者：

Seong-Ho Kong

Yukinori Kurokawa

Jeong-Hwan Yook

Haruhiko Cho

Oh-Kyoung Kwon

Toru Masuzawa

Kyung Hee Lee

Sohei Matsumoto

Young Soo Park

Hiroshi Honda

Seung-Wan Ryu

Takashi Ishikawa

Hye Jin Kang

Kazuhito Nabeshima

Seock-Ah Im

Toshio Shimokawa

Yoon-Koo Kang

Seiichi Hirota

Han-Kwang Yang

Toshirou Nishida

机构：

[1] Seoul National University Hospital,Department of Surgery, Cancer Research Institute

[2] Seoul National University College of Medicine Cancer Research Institute,Department of Gastroenterological Surgery

[3] Osaka University Graduate School of Medicine,Department of Surgery

[4] University of Ulsan College of Medicine Asan Medical Center,Department of Surgery

[5] Kanagawa Cancer Center,Department of Surgery

[6] Kyungpook National University School of Medicine,Department of Surgery

[7] Kyungpook National University Chilgok Hospital,Department of Hemato

[8] Osaka Police Hospital,Oncology

[9] Yeungnam University College of Medicine,Department of Surgery

[10] Nara Medical University,Department of Pathology

[11] University of Ulsan College of Medicine Asan Medical Center,Department of Surgery

[12] Sendai Open Hospital,Department of Surgery

[13] Keimyung University Dongsan Hospital,Department of Surgery

[14] Niigata University Graduate School of Medical and Dental Sciences,Department of Internal Medicine, Korea Institute of Radiological & Medical Sciences

[15] Korea Cancer Center Hospital,Department of Surgery

[16] Tokai University,Department of Internal Medicine

[17] Seoul National University Hospital and Seoul National University College of Medicine Cancer Research Institute,Clinical Study Support Center

[18] Wakayama Medical University Hospital,Department of Oncology

[19] University of Ulsan College of Medicine Asan Medical Center,Department of Surgical Pathology

[20] Hyogo Medical University School of Medicine,Department of Surgery

[21] Japan Community Health Care Organization Osaka Hospital,undefined

来源：

Gastric Cancer | 2023年 / 26卷

关键词：

Gastrointestinal stromal tumor; Imatinib mesylate; Neoadjuvant; Stomach neoplasm;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：775 / 787

页数：12

共 125 条

[11]

Nishida T(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-5405

[12]

Steigen SE(2007)Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors Clin Cancer Res 13 5398-1080

[13]

Brabec P(2012)Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132 Ann Surg Oncol 19 1074-2943

[14]

Boye K(2013)Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience Ann Surg Oncol 20 2937-1836

[15]

Berner JM(2021)Prognostic factors after neoadjuvant imatinib for newly diagnosed primary gastrointestinal stromal tumor J Gastrointest Surg 25 1828-2600

[16]

Hompland I(2010)Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST) Ann Surg Oncol 17 2585-1134

[17]

Bruland ØS(2004)Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127-615

[18]

Stoldt S(2008)Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer 112 608-1759

[19]

Sundby Hall K(2007)Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753-18

[20]

Blay JY(2013)Surgical treatment of gastric gastrointestinal stromal tumor J Gastric Cancer 13 3-70

← 1 2 3 4 5 6 7 8 9 10 →